B.Sc. (Chemistry), JD, LL.M.
Alan is a highly regarded U.S. intellectual property attorney, IP strategy analyst, legal advisor who advises clients in patent strategy, portfolio management, patent prosecution, trademark protection, copyright filings, and trade secret matters. Additionally, he regularly advises Wall Street investors for Fortune 500 companies. He has over 25 years of legal experience and over 20 years specializing in intellectual property law.
Working as the U.S. Patent Counsel for IPSEN located in Paris, France, Alan was responsible for all of IPSEN’s IP in the U.S. (Pharm & Biopharma); Ireland (Manufacturing); and Spain (Drug Delivery Technology). Alan joined PCK to lead their U. S. Life Sciences division. He has experience serving as in-house counsel, managing outside counsel, and working in private practices, including:
- Executive-level management in pharmaceutical and biotech industry with a major focus on Small & Large Molecule, Protein & Peptide, and Biological IP development
- Leading IP strategy and development for R&D teams in chemistry, biology, manufacturing processes, instruments, and drug delivery systems
- Chief US IP Counsel for multinational biopharmaceutical company with approx. thirty (30) affiliates world-wide
- Strong experience in drug discovery and development, peptide engineering, protein engineering, medicinal chemistry, biotechnology, project management, and alliance management for all aspects of IP portfolio management
- Strategy in dispute resolution and litigation
- Alan is a former member of the biotechnology and biomedical unit for the United States Patent and Trademark Office. He specializes in the procurement and enforcement of intellectual property rights, including patents, trademarks, and copyrights. Other scientific areas of his practice include molecular diagnostics, oncology, medical devices, mechanical and materials sciences.
Donald is the Executive Director for PCK Feeney Law a global intellectual property law firm dedicated to the advancement of life sciences and technology innovations. He is also the Founder and CEO of FRUENT.
As a successful entrepreneur, Donald works to expand PCK Feeney Law and FRUENT globally and is responsible for international strategic partnerships.
He specializes in startup and early to mid-stage companies with over 20 years of startup, development, and executive management experience in Life Sciences & Technology Startups, Global Business Development, and Commercialization. He has successfully developed three healthcare delivery companies and an Intellectual Property Law firm.
Prior to PCK Feeney Law , Donald co-founded Valor Healthcare and was Senior Vice President of MedMark Services. There he was responsible for the startup and operations of 28 outpatient and behavioral health clinics. Donald earned his Master of Public Health from A.T. Still University and his Bachelor of Science in Finance from Louisiana State University. He is an avid traveler and has lived in such diverse places.
BSc. Mathematics; MSc. Organic Chemistry; MSc Computer Science
Donna is an expert in the field of Intellectual Property Research Analytics and is well versed in multiple aspects of technical information handling in the pharma and biotech industries.
She has more than 20 years’ experience performing in-depth structure, sequence, and subject matter searches in the areas of pharmaceuticals and biotechnology. Her specialties are searching prior art for patentability, landscaping for competitive analysis and/or current awareness, and conducting freedom-to-operate and invalidity searches.
Tangentially, Donna also has extensive experience in developing custom applications for handling chemical and biological information as well as systems to enhance workplace productivity.
Sr Biologist/Oncologist (Director In Vivo Pharmacology) with Expertise in Peptide, Small Molecule, and Antibody PhilKPhil is an experienced, passionate senior level biologist/oncologist with leadership experience. He has been involved in the peptide, small molecule, and antibody fields. Phil also has extensive knowledge and experience in the Oncology and Pharmacology fields.
During his career, Phil has worked in both small (startup) and medium sized pharma and have lead research programs where team members were either internal, external (collaboration or CRO based) or a blend of both. Phil established and ran the in vivo Oncology department at Ipsen in the US managing a group of research associates and scientists and has been involved in numerous projects.
Beyond biology, Phil has been actively involved in both in-licensing and out-licensing of various company assets. With an out licensing team, we sold our in house topoisomerase projects to a large US pharma for $200M. He co-spearheaded another group to out license a preclinical cdc25 program to a medium sized European pharma for 40M.
Phil has also been involved in business development, partner and asset evaluation, alliance management, and therapeutic area company direction. Phil has a reputation and has repeatedly been recognized by upper management for promoting collaboration both within groups and across cross-functional teams. A people person by nature, he enjoys working with enthusiastic teams and spearheading effective collaborations to accelerate the drug discovery process.
Master of Science (M.S.), Pharmaceutical Chemistry
Aimee’s expertise is in peptide chemistry including the design, synthesis, purification, and characterization of peptides and peptide conjugates. She spent over six years working as a Senior Research Associate at a major life sciences multinational drug development firm. Her experience working on research programs from the concept assessment and IP strategy, to lead optimization stages, provided her with a 360 degree view of the drug development process. She leads our operational excellence in the workplace program and is instrumental in the design and implementation of various solutions for data capture, query, and analysis.
Langyu has over 30 years experience in research, development, and validation of analytical methods. She has worked in biotech, pharmaceutical, medical device, food, and analytical instrument companies. She is an accomplished contributor to the blockbuster TAXUS drug eluting stent, which was developed by Boston Scientific Corporation and approved by the FDA in 2004. She also involved in research and development of three magnetic resonance imaging contrast agents, which received FDA’s approval in 1990s. Langyu is now a senior consultant at Amphitide Inc.
Langyu’s expertise includes: drug delivery, in vitro drug release in different media, bioanalytical analysis of in vivo drug metabolites using LC/MS/MS (liquid chromatography and mass spectrometry), drug and stent stability study in compliance with USP guidelines, impurity and degradation profiles of API (active pharmaceutical ingredients), etc.
Langyu earned her Master of Science in Analytical Chemistry from Ohio University and her Bachelor of Science in Analytical Chemistry from Peking University.
PhD Mechanical Engineering
David specializes in analytical and experimental nonlinear dynamics, failure mechanics, modal testing and analysis, dynamics and stability of engineered systems. His emphasis is on synthesizing knowledge from fields such as dynamical and stochastic systems, linear and nonlinear time series analysis, multivariate analysis, estimation and filtering theory to develop and implement innovative techniques for modeling, simulation, diagnosis and prognosis of engineered and biological systems.
Juan Jose Barboza-Gubo
MFA Painting, MFA Sculpture
Juan Jose Barboza-Gubo received his Bachelors Degree at Pontificia Universidad Catolica del Peru. He has received two MFA degrees, one in Painting and one in Sculpture, both from Massachusetts College of Art and Design (graduating with a nomination for the Joan Mitchell Award in 2008). He has had numerous exhibitions in US, including shows at the Nielsen Gallery; The Art Institute of Boston at Lesley University; Chazan Gallery, Providence; The Fitchburg Museum; the Attleboro Museum; and the Brattleboro Museum and Art Center. His work has been featured internationally in galleries and museums in Tokyo, Athens, and Italy, as well as the Cecilia Gonzales Gallery of Lima, Peru. Recent awards of note include first prizes in the 2008 Ceramic Biennial of the New Hampshire Institute of Art, and the 78th Regional Exhibition at the Fitchburg Museum in 2014. Also in 2014 he was named the Breakout Artist of the Year by Artscope Magazine. Additionally, he was awarded the 2015 Rhode Island State Council on the Arts Fellowship in Painting, and the 2016 Rhode Island State Council on the Arts Fellowship in Sculpture. His exhibitions have been reviewed in such publications as The Boston Globe, Artscope Magazine, El Comercio, and many others. Barboza-Gubo currently teaches at Rhode Island College.